Gastroenteritis News and Research

RSS

Gastroenteritis (also known as gastro, gastric flu, and stomach flu) refers to inflammation of the gastrointestinal tract, involving both the stomach and the small intestine and resulting in acute diarrhea. The inflammation is caused most often by infection with certain viruses, less often by bacteria or their toxins, parasites, or adverse reaction to something in the diet or medication.

Researchers identify new cellular source for disease-fighting protein

Researchers at UT Southwestern Medical Center report the identification of a new cellular source for an important disease-fighting protein used in the body's earliest response to infection.

11 Jul 2013

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer Inc. announced today the company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), received European approval for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae).

10 Jul 2013

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform.

20 Jun 2013

Vaccine given to newborns 60% effective against rotavirus in Ghana

Mayo Clinic and other researchers have shown that a vaccine given to newborns is at least 60 percent effective against rotavirus in Ghana. Rotavirus causes fever, vomiting and diarrhea, which in infants can cause severe dehydration.

18 Jun 2013

Highly-infectious sickness bug can be killed by copper and copper alloys

New research from the University of Southampton shows that copper and copper alloys will rapidly destroy norovirus - the highly-infectious sickness bug. The virus can be contracted from contaminated food or water, person-to-person contact, and contact with contaminated surfaces, meaning surfaces made from copper could effectively shut down one avenue of infection.

28 May 2013

India's DBT, Bharat Biotech announce positive Phase III clinical trial results of rotavirus vaccine

The Government of India's Department of Biotechnology and Bharat Biotech announced positive results from a Phase III clinical trial of a rotavirus vaccine developed and manufactured in India.

14 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age.

From Pfizer, Inc. 29 Apr 2013

Luminex's MAGPIX instrument gets FDA approval

Luminex Corporation today announced it has received U.S. FDA clearance of its MAGPIX instrument, with its xTAG Gastrointestinal Pathogen Panel.

From Luminex 16 Apr 2013

Researchers test protease inhibitors with potential for prevention, treatment of norovirus infection

A Kansas State University-led team is researching ways to stop the spread of norovirus, a contagious stomach illness that infects one in 15 Americans each year, according to the Centers for Disease Control and Prevention.

25 Mar 2013

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197 Protein)in adults infected with human immunodeficiency virus (HIV).

5 Mar 2013

GP consultations: an interview with Associate Professor Helena Britt, University of Sydney

Well it hasn’t varied at all over the last 15 years, which I find pretty amazing because we’ve been through a lot of changes in general practice. Yet, the average length of consultation, as measured from a start to finish time, in a sample of 40,000 consultations in Australia in a year, shows that the average is 15 minutes and the median is 13 minutes.

4 Mar 2013

General practitioners ‘may miss UTI in children’

Family doctors need to lower their threshold of suspicion for urinary tract infection in children, according to UK research.

18 Feb 2013

Luminex consolidated fourth quarter revenue increases 16% to $55.5 million

Luminex Corporation today announced financial results for the fourth quarter and year ended December 31, 2012.

From Luminex 4 Feb 2013

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.

28 Jan 2013

Trauma, infection link with stroke seen in children

Research shows that trauma and acute infection are significant risk factors for arterial ischemic stroke in children.

8 Jan 2013

Study finds specific way in which Salmonella counteract defense mechanisms of human cells

A new study by researchers at Imperial College London has identified a way in which Salmonella bacteria, which cause gastroenteritis and typhoid fever, counteract the defence mechanisms of human cells.

16 Nov 2012

Canadian Cardiovascular Society issues new pediatric heart failure guidelines

The Canadian Cardiovascular Society is the first in Canada to issue guidelines aimed at helping primary care and emergency physicians, as well as specialists, recognize and manage heart failure in children. The guidelines were released today at the Canadian Cardiovascular Congress.

30 Oct 2012

Link between norovirus outbreaks and excess hospitalization and mortality in nursing homes

In a study that included more than 300 Medicare-certified nursing homes, rates of hospitalization and death were substantially increased during outbreaks of norovirus gastroenteritis vs. non-outbreak periods, according to a study appearing in the October 24/31 issue of JAMA.

19 Oct 2012

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.

5 Oct 2012